Testing requires recombinant OCTN2 transport assays with competitive inhibition kinetics (Lineweaver–Burk analysis), 14C-carnitine uptake studies in OCTN2-overexpressing cancer cell lines, metabolomic profiling of β-oxidation flux and AMPK activation upon lipopeptide treatment, and xenograft studies comparing lipopeptide monotherapy and chemotherapy combination. This evidence concerns the gene SLC22A5 and cancer.